IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Rhea-AI Summary
IMUNON (Nasdaq: IMNN) will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its Phase 3 clinical program for IMNN-001.
To join, dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and reference Conference ID 4157104; a live webcast and a 90-day audio replay will be available. According to the company, the call will review 2025 results and clinical progress for IMNN-001.
Positive
- None.
Negative
- None.
News Market Reaction – IMNN
In the Mar 24 session, IMNN declined 1.34%, reflecting a mild negative market reaction. Argus tracked a peak move of +14.1% during that session. Argus tracked a trough of -27.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 57.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 call scheduled | Neutral | -1.0% | Announced Q3 2025 results and business update call with clinical program focus. |
| Aug 05 | Q2 2025 call recap | Positive | -6.2% | Recapped Q2 call, noting OVATION 3 progress, stock dividend, and capital raises. |
| Jul 29 | Q2 2025 call scheduled | Neutral | +8.9% | Scheduled Q2 2025 financial results call with IMNN-001 Phase 3 updates. |
| May 05 | Q1 2025 call scheduled | Neutral | +1.4% | Announced Q1 2025 results call and clinical development program discussion. |
| Feb 20 | 2024 results call set | Neutral | -1.5% | Set date for 2024 full-year results and business update conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past conference/earnings-related announcements have generally led to modest single-digit moves with a mix of small gains and losses.
Over the past year, IMUNON has repeatedly used conference and earnings calls to update investors on IMNN-001 and its Phase 3 ovarian cancer program. Events on Feb 27, 2025, May 12, 2025, Aug 5, 2025, Nov 6, 2025, and the subsequent Q2 recap all combined routine financial reviews with clinical progress commentary and access details for webcasts and replays. Today’s scheduled full-year 2025 results and business update call on Mar 31, 2026 continues this pattern of structured, periodic communication.
Key Terms
dna-mediated immunotherapy medical
immunotherapy medical
interleukin-12 (il-12) medical
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.
The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and ask for the IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live webcast of the call will also be available here.
An audio replay of the call will be available for 90 days and can be accessed at 800-770-2030 (U.S. and Canada/Toll Free), 609-800-9909 (U.S./Toll) or 647-362-9199 (Canada/Toll) using replay access code 4157104#.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
